Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00507130 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00507130 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 36 participants.
The verdict
NCT00507130, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of escalating multiple SC doses of MEDI-528 in adult patients with mild persistent asthma.
Interventions
- OTHER PLACEBO
- BIOLOGICAL MEDI528 0.3 mg/kg
- BIOLOGICAL MEDI528 1 mg/kg
- BIOLOGICAL MEDI528 3 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00507130
The ClinicalTrials.gov registry entry for NCT00507130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PLACEBO is the first listed.
NCT00507130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00507130 about?
NCT00507130 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma". The primary objective of this study is to evaluate the safety and tolerability of escalating multiple SC doses of MEDI-528 in adult patients with mild persistent asthma.
What is the current status of trial NCT00507130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2007-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00507130?
The interventions under investigation include: PLACEBO (OTHER), MEDI528 0.3 mg/kg (BIOLOGICAL), MEDI528 1 mg/kg (BIOLOGICAL), MEDI528 3 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00507130?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.